Are you living with non-Hodgkin lymphoma that has returned or stopped responding to treatment? Learn about a study of a new treatment option.

Who can take part?

• Adults aged 18 years and older
• Diagnosed with non-Hodgkin lymphoma that has returned or stopped responding to treatment
• Have received at least two previous lines of treatment (some lymphoma subtypes may require at least one prior treatment).

• Active lymphoma involving the brain or spinal cord
• Previous stem cell transplant from a donor
• CAR T-cell therapy within the previous 60 days
• Active or uncontrolled infection
• Significant heart disease or poorly controlled high blood pressure
• Active lung conditions that may increase study risk
• Pregnant or breastfeeding
• Another active cancer that may interfere with participation
• Any medical condition that the study doctor considers may make participation unsuitable

What is involved for me?

• Daily oral ARV-393 treatment in 28-day cycles.
• Some participants may also receive glofitamab by intravenous (IV) infusion.
• Follow-up visit approximately 1 month after treatment ends
• Long-term follow-up every 3 months for up to 2 years
• Visits occur weekly or every 2 weeks during the first few treatment cycles.
• CT/PET scans every 8 weeks during the first year, then every 12 weeks.
• Blood tests, urine tests and vital signs at each visit
• Regular physical examinations and heart monitoring.